(Q47952691)

7 February 2018

title

The potential for cancer combination therapy with multi-targeted, single-protein pharmaceuticals (English)

1 reference

7 February 2018

author name string

Jeffrey Way

series ordinal

1

1 reference

7 February 2018

Michael Super

series ordinal

2

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 February 2008

1 reference

7 February 2018

Expert Opinion on Drug Discovery

published in

1 reference

7 February 2018

volume

3

1 reference

7 February 2018

issue

2

1 reference

7 February 2018

page(s)

147-152

1 reference

7 February 2018

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Design and production of novel tetravalent bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.2.147

21 January 2018

Identifiers

DOI

10.1517/17460441.3.2.147

1 reference

7 February 2018

1 reference

7 February 2018